{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-039826","form_type":"8-K","ticker":"CATX","cik":"0000728387","company_name":"Perspective Therapeutics, Inc.","filed_at":"2025-03-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:06.212212+00:00","generated_at":"2026-05-24T17:11:10.228570+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Perspective Therapeutics doses first patient in [212Pb]VMT01 plus nivolumab combo cohort","bullets":["First patient dosed with [212Pb]VMT01 at 1.5 mCi in combination with nivolumab (Opdivo) for MC1R+ metastatic melanoma Phase 1/2a trial.","Earlier monotherapy cohorts showed no dose-limiting toxicities and early signs of anti-tumor activity, presented at SMR October 2024.","FDA granted Fast Track Designation for [212Pb]VMT01 in unresectable or metastatic melanoma with MC1R expression in September 2024.","New cohort explores dual mechanism of targeted alpha-particle therapy plus PD-1 blockade to improve patient outcomes."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-039826","json":"https://secwatch.observer/filing/0000950170-25-039826.json","markdown":"https://secwatch.observer/filing/0000950170-25-039826.md","text":"https://secwatch.observer/filing/0000950170-25-039826.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/728387/000095017025039826/0000950170-25-039826-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/728387/000095017025039826/catx-20250317.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T17:11:10.228570+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}